Shattuck Labs, Inc. 8K

Shattuck Labs reported Q2 2026 results, highlighted advancement of DR3-focused drug candidates SL-325 and SL-846, and disclosed a significantly strengthened cash position expected to fund operations into 2029.

On August 11, 2026, Shattuck Labs, Inc. reported its financial results for the quarter ended June 30, 2026 and provided business updates, including positive Phase 1 data for its lead DR3-blocking antibody SL-325 supporting advancement into a Phase 2b Crohn’s disease trial expected to start in the third quarter of 2026, progress on its bispecific DR3 x IL-23R candidate SL-846 with IND-enabling GLP toxicology underway and initial clinical data targeted for 2027, and a strengthened balance sheet of approximately $208.3 million in cash, cash equivalents, and short-term investments following an $86.2 million underwritten public offering and $57.1 million in warrant exercise proceeds, which the company expects will fund operations into 2029 despite ongoing net losses.

Filing Facts

CIK

1680367

Ticker

STTK

Form

8K

Source Type

fda

Accession

0001628280-26-055484

Alert Tier

6